Products

Inspiremarks

Influencer Marketing

inspiremarks.com Marketing / Influencer & UGC Marketing

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
MRR
$100Claimed
Disclosed 2026-09-29Indie Hackers
Entry price
Unknown
Freemium model, plan pricing not identified yet
Creators
Bobby Cavezza
@inspiremarks· 1 followers
Launched
2y ago
2024-10-13 · Est.

Traffic & revenue

Monthly visitsData through Oct 2026
MRRSelf-reported, unverified · Indie Hackers
  • Sep 2026$100Self-reported MRR · unverified
Events1 revenue disclosure

Revenue evidence

Publicly disclosed & verified revenue figures, sorted by date

Marketing moves

Launches, search & content, referrals, promotions
X accounts@inspiremarks
  • New product launchLaunch

    Oct 13, 2024 · 2y agoWebsite

Traffic sources

Oct 2026

Traffic breakdown

Channels

  • Organic Search38%
  • Direct27%
  • Referrals14%
  • Display Ads7%
  • Other14%

Countries

  • Japan100%

Search

Domain authority 0Domain registered 2024-10-13

KeywordMonthly volume
inspiremarks150

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Pages & changes

Tracked since 2026-08-10

Key pages

Weekly snapshots
Home
inspiremarks.com/ Snapshot 2026-11-04

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does Inspiremarks get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Inspiremarks and what platforms does it support?
Inspiremarks is catalogued under Influencer & UGC Marketing: Influencer Marketing. Supported platforms: Web.
What is Inspiremarks's publicly disclosed revenue?
Indie Hackers records a founder-reported figure of $100 /mo stated on 2026-09-29.Source

Related products in this category

Marketing / Influencer & UGC Marketing

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.